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Abstract
Purpose The purposes of this study, in children who were
assessed 1 week after the administration of myelosuppres-
sive chemotherapy were: to compare the total and subscale
scores on a generic measure of health-related quality of life
(HRQOL) to normative data from healthy children and
describe the relationships between demographic, clinical,
and symptom characteristics of children with cancer and
generic and disease-specific dimensions of HRQOL.
Methods Patients (n=61) were predominantly male
(52.5%), minority (63.9%), and 14.7 years of age. Children
completed the Memorial Symptom Assessment Scale for
10- to 18-year olds, the PedsQL™ Generic and Cancer
Modules, and the Karnofsky Performance Status (KPS)
scale 1 week after the start of a chemotherapy cycle.
Results The mean number of symptoms per patient was
10.6. Compared with the normative sample, children with
cancer reported significantly lower scores for the total scale
and all of the subscales except emotional and social
functioning. No significant differences were found between
any demographic characteristics and total or subscale scores
on the generic or disease-specific measures of HRQOL.
Lower KPS scores were associated with poorer generic and
disease-specific HRQOL scores. In addition, a higher
number of symptoms was associated with poorer generic
and disease-specific HRQOL scores. Finally, higher symp-
tom distress scores were associated with poorer generic and
disease-specific HRQOL scores.
Conclusion Among the demographic, clinical, and symp-
tom characteristics studied, poorer functional status and
higher symptom burden were associated with significant
decreases in HRQOL in children who received myelosup-
pressive chemotherapy.
Keywords Health-related qualityoflife.Karnofsky
PerformanceStatus.Myelosuppressivechemotherapy
Introduction
Collectively, the physical and psychosocial well-being of
individuals receiving health care is termed health-related
quality of life (HRQOL). This concept differs from the
broader concept of overall quality of life which may include
environmental, political, or economic issues in addition to
health-related concerns [1]. The inclusion of HRQOL as an
evaluable endpoint in cancer treatment and symptom
management trials is important for a number of reasons. It
can be used as part of an evaluation of the effectiveness of a
treatment or to discriminate between two treatments with
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DOI 10.1007/s00520-010-0824-yequivalent efficacy, but different toxicity profiles. This
information can be used in a shared decision-making process
with children and parents, because even small changes in
HRQOL that occur early in a child's life may cause large
cumulative effects over time in quality-of-life years lost [2].
Prior to 2000, very few clinical trials with pediatric
oncology patients evaluated HRQOL as a study endpoint
[3]. However, at the present time, many Phase III
chemotherapy (CTX) trials collect data on HRQOL to
supplement data on survival rates. In addition, HRQOL
endpoints are being used in nearly 75% of oncology
symptom management trials [4] as a result of a mandate
by the Food and Drug Administration to include patient
reported outcomes (PROs) in clinical trials [5, 6].
Most HRQOL research in pediatric oncology focuses on
survivors of childhood cancer [7]. Only a limited number of
studies have identified the factors that affect HRQOL in
children who are receiving active cancer treatment [8–17].
Only four of these studies included patients receiving
intensive CTX [8, 10, 15, 18], and none included children
who received only myelosuppressive CTX. Some informa-
tion, albeit limited in quantity, is available regarding the
relationships between demographic (e.g., age, gender) and
clinical characteristics (e.g., treatment status, comparisons
among various cancer diagnoses) and HRQOL of children
who received cancer CTX. In addition, the relationships
among functional status, symptom occurrence rates, and
HRQOL of children with cancer were assessed in only one
study [19]. Therefore, the purposes of this study, in children
who were assessed 1 week after the administration of
myelosuppressive CTX were: to compare the total and
subscale scores on a generic measure of HRQOL (i.e., the
Pediatric Quality of Life Inventory 4.0 Generic Core Scale)
to normative data from healthy children and to describe the
relationships between demographic, clinical, and symptom
characteristics of children with cancer and generic and
disease-specific dimensions of HRQOL. It was hypothe-
sized that the HRQOL scores of children with cancer would
be lower than those of healthy children.
Patients and methods
Patients and procedures
This descriptive study used self-report questionnaires to
obtain information from a convenience sample of children
and adolescents with cancer (10 to 18 years of age) who
were able to understand English or Spanish and give assent
or consent to participate and were receiving myelosuppres-
sive CTX. Participants were receiving CTX either as their
initial therapy or for relapsed or refractory disease and had
received at least one prior course of CTX. Children younger
than 10 years of age were excluded because the instrument
used to evaluate symptoms was validated in patients
between the ages of 10 and 18 years.
Myelosuppressive CTX refers to treatment that is
expected to cause a significant drop in the absolute
neutrophil count to less than 500 cells/μL, with subsequent
blood count recovery expected to occur within 3 to 4 weeks.
Similar CTX regimens were targeted for selection among
common diagnoses (e.g., doxorubicin with cisplatin for
osteosarcoma and cyclophosphamide with cytarabine for
acute lymphocytic leukemia). Patients were excluded if
they were receiving concurrent radiation therapy. Patients
were recruited from three pediatric oncology settings in the
San Francisco Bay area.
Between February 2008 and February 2009, a total of 73
patients were approached to participate, and 66 provided
assent or consent (response rate of 91.4%). Of the eligible
patients available, approximately eight were not approached
because research staff were not available at the site. The
primary reason for refusal was that patients were not
interested in completing questionnaires. While data were
collected weekly over a 3-week period (i.e., prior to the
administration of CTX, 1 week following CTX administra-
tion, and 2 weeks following CTX administration), the
HRQOL data reported in this paper is from the second time
point (i.e., the week following CTX administration).
Patients' symptoms were expected to be the most frequent
and severe at this time point. In addition, previous research
found the HRQOL of pediatric oncology patients was
lowest in the days immediately following CTX [8].
The study was approved by the Human Subjects
Committee at the University of California, San Francisco,
and at each of the study sites. Patients' parents or guardians
and patients who were 18 years of age signed a written,
informed consent. Patients aged 10 to 17 (85%) gave either
written or verbal assent as per each institution's guidelines.
One week after the administration of CTX, children
completed the Memorial Symptom Assessment Scale for
10- to 18-year olds (MSAS 10–18) [20]. In addition, they
completed the age-appropriate versions of the Pediatric
Quality of Life Inventory 4.0 Generic Core Scale
(PedsQL™ 4.0 GCS) [21, 22], the Pediatric Quality of
Life Inventory 3.0 Cancer Module Scale (PedsQL™ 3.0
Cancer) [23], the Karnofsky Performance Status (KPS)
scale [24], and a weekly data form to capture information
not uniformly included in the medical record (e.g., number
of hospitalizations, fever). Children were asked to respond
to each question based on their experiences during the week
following CTX administration. Children received support
from the the research assistants to complete the study
questionnaires as needed in person (if the patients were
hospitalized or had clinic appointments) or via telephone.
English and Spanish versions of the PedsQL™ were
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Spanish using forward and backward translation proce-
dures. Patients’ medical records were reviewed for disease
and treatment information. The children were given a $50
gift card to compensate them for their time.
Instruments
The revised version of the MSAS 10–18 assesses 31
symptoms on three dimensions. If patients reported the
occurrence of a symptom over the previous week, they
rated the symptom's frequency (1 (almost never) to 4
(almost always)), severity (1 (slight) to 4 (very severe)), and
distress (0 (not at all) to 4 (very much)) using Likert scales.
Positive responses were summed to determine the total
number of symptoms experienced. Severity and distress
ratings were assigned a value of zero when the symptom
was not reported. The severity and distress ratings for all 31
symptoms were averaged to calculate the mean ratings for
these two dimensions. The MSAS 10–18 was chosen
because it is a multidimensional symptom inventory that
evaluates 31 symptoms, yet can be completed in less than
15 min [20]. The MSAS 10–18 has established validity and
reliability [20].
The PedsQL™ is a modular instrument that consists of a
generic measure and disease-specific modules. The
generic version of the instrument (i.e., PedsQL™ 4.0
GCS) has been used extensively to assess HRQOL in
both healthy and chronically ill children with a variety of
medical conditions, including cancer. It is a 23-item
instrument that evaluates the following dimensions of
HRQOL: physical, emotional, social, and school func-
tioning [21, 22]. In this study, the acute version of the
instrument was used. Patients responded using the time
frame of the past 7 days, using 5-point Likert scales (i.e., 0
(never a problem) to 4 (almost always a problem)). Items
are reverse scored and linearly transformed to a 0 to 100
scale, with higher scores indicating a better HRQOL. A
total and four subscale scores are calculated (i.e., physical
functioning, emotional functioning, social functioning,
school functioning).
The cancer-specific instrument used in this study was the
PedsQL™ 3.0 Cancer Module Acute Version [23], a 27-
item multidimensional survey with eight subscales (i.e.,
pain and hurt, nausea, procedural anxiety, treatment anxiety,
worry, cognitive problems, perceived physical appearance,
communication). The response format and scoring proce-
dures are similar to those for the PedsQL™ 4.0 GCS.
Each of the HRQOL instruments takes less than 5 min to
complete. Both forms of the PedsQL™ have established
validity and reliability [21–23]. In this sample, Cronbach's
alpha coefficients for the PedsQL™ generic and cancer
versions were 0.89 and 0.90, respectively.
The KPS scale was used to assess patients' functional
status. KPS scores range from 0 (dead) to 100 (normal
function) in 10-point increments [24]. The KPS has well-
established validity and reliability in adults [25–28] and has
been used in pediatric studies [19, 29–31].
Analytic methods
Data were analyzed using SPSS® version 15.0 (SPSS, Inc.,
Chicago, IL). Descriptive statistics were generated on the
sample characteristics. Because HRQOL scores did not differ
significantly by study site, or language, data were analyzed for
t h ee n t i r es a m p l e .O n es a m p l et tests were used to compare
total and subscale scores on the PedsQL™ between children
with cancer and normative data on healthy children.
Independent samples t tests and Pearson's product-moment
correlations were used to examine the relationships between
demographic characteristics (i.e., age, gender, race/ethnicity),
clinical characteristics (i.e., number of inpatient days, number
of relapses, KPS scores), and symptom characteristics (i.e.,
number of symptoms, mean symptom severity, mean
symptom distress) and generic and disease-specific measures
of HRQOL. In order to control the type I error rate, a p value
of <0.01 was considered statistically significant.
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the patients
(n=61) are summarized in Table 1. The majority of the
children were male (52.5%), a member of a racial/ethnic
minority (63.9%), with a mean age of 15 years, and an
average KPS score of 81.7. Children were diagnosed with a
wide range of cancers and 78.6% were receiving their initial
treatment. Most treatment was delivered in the inpatient
setting (67.2%).
Symptom characteristics
Patients' experienced a mean of 10.6 symptoms (standard
deviation (SD)=4.1) in the prior week. Across the 31
symptoms, the mean severity and distress ratings were 0.7
and 0.6, respectively (possible range, 0 to 4). The five most
common symptoms were: nausea (80.3%), fatigue (70.5%),
pain (68.9%), alopecia (65.6%), and feeling drowsy (57.4%).
Differences in generic HRQOL between children
with cancer and healthy children
As shown in Table 2, children with cancer reported
significantly lower scores for the total score, physical
Support Care Cancer (2011) 19:353–361 355functioning, and school functioning subscales of the
PedsQL™ than the normative sample of healthy children
[32]. No between group differences were found for the
emotional functioning and social functioning subscales. In
addition, previously established criteria for clinically
meaningful decreases in PedsQL™ GCS scores [32] are
listed in Table 2. These criteria were met for the total,
physical functioning, and school functioning scores.
Relationships between demographic characteristics
and generic and disease-specific measures of HRQOL
As shown in Table 3, no significant differences were found
between age groups, genders, and race/ethnicity groups on
any total or subscale scores for the generic or disease
specific measures of HRQOL.
Relationships between clinical characteristics and generic
and disease-specific measures of HRQOL
As shown in Table 4, the only HRQOL score that was
correlated with the number of days hospitalized in the past
week was nausea, such that children who were hospital-
ized longer reported higher levels of nausea. No signifi-
cant relationships were found between number of relapses
and any of the HRQOL scores. KPS scores were
positively correlated with the total and most of the
subscale scores of the generic HRQOL measure (i.e., all
subscales except emotional functioning and school func-
tioning) and with the total and nausea subscale of the
disease-specific measure.
Relationships between symptom characteristics and generic
and disease-specific measures of HRQOL
The total and subscale scores for the PedsQL™ 3.0 Cancer
module, for this sample, are illustrated in Fig. 1. As shown
in Table 4, significant negative correlations were found
between the total number of symptoms and the total and all
of the subscale scores of the generic HRQOL measure
Table 1 Demographic and clinical characteristics of the sample (n=61)
Age (years)
Mean (SD) 14.7 (2.8)
Range 10–18
Median 15.3
Number of symptoms
Mean (SD) 10.6 (4.1)
Range (possible range 0–31) 1–22
Median 10.0
Symptom severity
a
Mean (SD) 0.7 (0.4)
Range (possible range 0–4) 0.1–1.7
Median 0.5
Symptom distress
a
Mean (SD) 0.6 (0.4)
Range (possible range 0–4) 0.0–1.8
Median 0.4
Karnofsky performance status scores
Mean (SD) 81.7 (16.7)
Range 30–100
Median 90
Number of days hospitalized in prior week
Mean (SD) 2.5 (2.5)
Range 0–7
Median 2.0
Time since diagnosis (months)
Mean (SD) 14.6 (29.7)
Range 0.5–132.4
Median 3.2
Gender
Male 32 (52.5%)
Female 29 (47.5%)
Race/ethnicity
b
White 22 (36.1%)
Hispanic 23 (37.7%)
Mixed race 7 (11.5%)
Asian 6 (9.8%)
Black or African American 2 (3.3%)
Native Hawaiian or other Pacific Islander 1 (1.6%)
Diagnoses
Acute lymphoblastic leukemia 15 (24.5%)
Osteosarcoma 10 (16.4%)
Ewing sarcoma 7 (11.5%)
Non-Hodgkin lymphoma 7 (11.5%)
Other solid tumors 7 (11.5%)
Central nervous system tumors 4 (6.6%)
Rhabdomyosarcoma 3 (4.9%)
Acute myeloid leukemia 3 (4.9%)
Hodgkin disease 3 (4.9%)
Other leukemia 2 (3.3%)
Number of relapses
0 48 (78.7%)
1 7 (11.5%)
≥2 6 (9.8%)
Chemotherapy-administered inpatient
Yes 41 (67.2%)
No 20 (32.8%)
aCalculation of mean scores included zero
bRace/ethnicity reported by parents
Table 1 (continued)
356 Support Care Cancer (2011) 19:353–361except the school functioning subscale, such that a higher
number of symptoms was associated with poorer HRQOL.
In terms of the cancer-specific measure, significant negative
correlations were found between total number of symptoms
and the total score and nausea subscale scores. A similar
pattern was noted for mean symptom severity.
Signficant negative correlations were found between
symptom distress and the total and most of the subscale
scores of the generic HRQOL measure except the school
functioning subscale. For the cancer-specific module,
significant negative correlations were found between
symptom distress and the total score and nausea and
cognitive problems subscale scores.
Discussion
To our knowledge, this study is the first to describe the
relationships between functional status and a number of
symptom characteristics and generic and disease-specific
measures of HRQOL in a relatively homogeneous sample
of children who underwent myelosuppressive CTX. The
effect sizes for differences in pediatric oncology patients’
physical subscale scores compared to those of healthy
children were greater than for the psychosocial subscales.
Based on a cutoff score of 1 SD below the population
norm, over 75% of children in this study met this cutoff for
the physical functioning subscale score and over 25% met
this cutoff for the total, emotional functioning, and school
functioning scores (Table 2). In addition, for the total,
physical functioning, and school functioning scores, these
differences met previously established criteria for clinically
meaningful decreases in HRQOL [32]. These findings are
similar to those reported for children with brain tumors
during their first year after diagnosis [17], children with
brain tumors on and off treatment [33], and for a
heterogeneous sample of children receiving active treatment
for cancer [15].
An interesting finding from this study, that is consistent
with previous reports, is that no between group differences
were found in children's scores on the emotional [17, 33]
and social functioning [17] subscales of the PedsQL™
generic version. Our quantitative data support the hypoth-
esis proposed by Penn et al. [17], that children with cancer
may not understand the consequences of their malignancy;
may repress symptoms of emotional distress; or may be
reluctant to provide details of their emotional state [17].
Alternatively, children with cancer may develop an as-
tounding degree of resiliency [34]. Additional investiga-
tions are warranted, perhaps using qualitative research
methods that explore the impact of cancer and its treatment
on children's emotional and social functioning.
In terms of the cancer-specific HRQOL measure, the
worst scores reported were for nausea (68.9), worry (69.5),
and pain and hurt (72.3). Only three studies have reported
subscale scores on the PedsQL™ cancer module from
children during CTX [11, 23, 35]. Our findings are similar
to most of those reported in previous studies. However,
children in this study reported less nausea and procedural
anxiety than Brazilian children on CTX [35]. The support-
ive care interventions readily available in the United States
(e.g., general anesthesia during invasive procedures, more
routine use of antiemetics) may explain these differences. In
addition, compared to data from Varni et al. [23], our
sample reported less procedural anxiety than children on
CTX in the late 1990s. General anesthesia was not
commonly used for invasive procedures at that time. Future
studies need to evaluate HRQOL in relationship to various
supportive care measures and how these scores change over
the course of cancer treatment and into survivorship.
The lack of many gender [36–38] and racial/ethnic
differences [39] in generic and disease-specific dimensions
Table 2 Differences in PedsQL™ 4.0 generic core scales between oncology patients and a normative sample of children
Oncology sample Normative data
a,b
Dimension N Mean SD Percent 1SD
below
normative mean
Percent 2SD
below
normative mean
N Mean SD tp value Effect
size
Minimal clinically
important
difference
a
Total score 60 68.0 17.3 43.3% 31.7% 5,079 83.91 12.47 −7.12 <0.001 1.27 4.36
Physical functioning 61 57.7 23.7 78.7% 57.4% 5,070 87.77 13.12 −9.89 <0.001 2.26 6.66
Emotional functioning 61 76.1 21.8 27.9% 9.8% 5,068 79.21 18.02 −1.13 0.265 0.17 8.94
Social functioning 60 81.7 15.7 18.3% 5.0% 5,056 84.97 16.71 −1.63 0.109 0.20 8.36
School functioning 53 63.4 25.6 54.7% 26.4% 5,026 81.31 16.09 −4.80 <0.001 1.10 9.12
SD standard deviation
aData from Varni et al. [32];
bEffect size calculation: (normative mean–oncology mean)/pooled SD
Support Care Cancer (2011) 19:353–361 357of HRQOL are consistent with previous reports of children
with cancer who received CTX. To date, only four studies
have identified gender differences in HRQOL. Girls
reported lower HRQOL scores than boys on various
subscales in three of these four studies [15, 39, 40]. In
addition, in two studies [36, 37], white children reported
better HRQOL than children from racial/ethnic minority
groups. While a few studies found that older children
reported a poorer HRQOL, these differences were generally
in the psychosocial dimensions [15, 37, 41–43], and were
contradicted by other studies [36, 39, 42]. These inconsis-
tent findings may relate to variations in the HRQOL
instruments used, comparisons between children's self-
reports and proxy reports, and small sample sizes. While
few differences in HRQOL were noted when demographic
characteristics were compared in a large population-based
study of the PedsQL™ [32], these inconsistent findings in
oncology patients warrant additional investigation.
Interms of clinical characteristics,while the number of days
hospitalized and the number of relapses were not associated
with any generic or disease-specific dimensions of HRQOL
except nausea, children with lower KPS scores reported
significantly poorer scores on almost every generic dimension
of HRQOL. The strongest correlations were found with the
physical and social functioning dimensions of the generic
measure. Clinicians' familiarity with the KPS, its simplicity of
use, and the strong correlations with HRQOL make it an ideal
metric to include in additional HRQOL research.
The moderate correlations between the various symptom
characteristics and the various dimensions of the generic
Table 3 Relationships among PedsQL™ total and subscale scores and demographic characteristics
Age Gender Race
<13years ≥13years Male Female White Others
PedsQL™ 4.0 Generic Core Scales
Total score 67.9 (16.5) 68.1 (17.9) 68.9 (17.1) 67.1 (17.7) 65.2 (17.3) 69.7 (17.3)
t=0.05 p=0.96 t=0.40 p=0.69 t=−0.96 p=0.34
Physical functioning 56.4 (21.3) 58.4 (25.0) 58.1 (24.6) 57.3 (23.2) 53.3 (24.0) 60.2 (23.5)
t=0.31 p=0.76 t=0.13 p=0.90 t=−1.10 p=0.28
Emotional functioning 77.8 (24.8) 75.2 (20.5) 76.4 (21.4) 75.7 (22.6) 75.5 (21.3) 76.4 (22.4)
t=−0.42 p=0.68 t=0.13 p=0.90 t=−0.16 p=0.87
Social functioning 81.8 (13.9) 81.6 (16.7) 81.3 (16.3) 82.1 (15.4) 80.2 (18.5) 82.5 (14.1)
t=−0.03 p=0.98 t=−0.22 p=0.83 t=−0.54 p=0.59
School functioning 62.5 (23.5) 65.6 (27.1) 66.4 (25.9) 62.2 (25.6) 57.3 (24.6) 68.8 (25.6)
t=0.43 p=0.67 t=0.60 p=0.55 t=−1.62 p=0.11
PedsQL™ 3.0 Cancer Module
Total score 77.6 (14.3) 75.9 (14.9) 77.6 (15.8) 75.3 (13.4) 76.3 (17.9) 76.6 (12.7)
t=−0.42 p=0.67 t=0.60 p=0.55 t=−0.09 p=0.93
Pain and hurt 79.4 (20.4) 68.9 (28.9) 76.2 (26.3) 68.1 (27.1) 67.0 (33.5) 75.3 (21.9)
t=−1.45 p=0.15 t=1.18 p=0.24 t=−1.17 p=0.25
Nausea 72.0 (19.1) 67.3 (25.7) 66.6 (27.0) 71.4 (19.6) 65.0 (25.5) 71.0 (22.7)
t=−0.72 p=0.47 t=−0.79 p=0.43 t=−0.95 p=0.34
Procedural anxiety 67.5 (28.3) 77.6 (29.0) 83.6 (23.5) 64.1 (31.3) 72.7 (33.8) 75.2 (26.2)
t=1.29 p=0.20 t=2.73 p=0.01 t=−0.32 p=0.75
Treatment anxiety 89.2 (20.6) 82.5 (24.4) 83.3 (25.5) 86.3 (20.8) 81.8 (29.3) 86.4 (19.2)
t=−1.05 p=0.30 t=−0.49 p=0.63 t=−0.73 p=0.47
Worry 74.6 (25.6) 67.1 (24.8) 66.9 (26.7) 72.4 (23.3) 72.3 (28.2) 67.9 (23.4)
t=−1.10 p=0.28 t=−0.85 p=0.40 t=0.66 p=0.52
Cognitive problems 83.8 (15.8) 78.8 (15.8) 80.9 (15.5) 79.8 (16.5) 78.4 (16.9) 81.5 (15.3)
t=−1.16 p=0.25 t=0.28 p=0.78 t=−0.73 p=0.47
Perceived physical appearance 80.8 (25.5) 83.5 (17.4) 87.5 (17.3) 77.3 (22.1) 90.5 (13.2) 78.2 (22.3)
t=0.49 p=0.63 t=2.01 p=0.05 t=2.72 p=0.01
Communication 74.2 (26.5) 83.5 (20.7) 80.2 (24.8) 80.7 (21.1) 85.2 (20.1) 77.8 (24.3)
t=1.51 p=0.14 t=−0.09 p=0.93 t=1.22 p=0.23
358 Support Care Cancer (2011) 19:353–361HRQOL measure suggest that the total number of symp-
toms, as well as severity and distress associated with these
symptoms have a negative effect on children’s HRQOL. On
average, children in this study reported ten symptoms in the
week following the administration of CTX. While the mean
symptom severity (0.7) and distress (0.6) scores were
relatively low, these scores included ratings on all 31
symptoms with zeros for symptoms that were not present.
Our findings are consistent with previous reports that found
that higher symptom severity and interference scores were
associated with poorer HRQOL in a sample of children
who were on and off therapy [19], as well as in a study of
adolescents and young adults with cancer and blood
disorders [44].
A study of the associations between symptom character-
istics and HRQOL poses some conceptual challenges. First,
the issue of the causal relationships between symptom
number, severity, and distress and decrements in HRQOL
are difficult to differentiate. Clearly, some symptoms may
cause decrements in HRQOL (e.g., nausea may cause poor
HRQOL). However, HRQOL may also affect symptom
occurrence (e.g., insomnia or anxiety may be caused by
decrements in the social functioning or school functioning
dimensions of HRQOL) [45]. In addition, many HRQOL
measures, like the measure used in this study, include one
or more dimensions that evaluate symptoms. Future studies
that include a longitudinal evaluation of both symptom
characteristics and various dimensions of HRQOL and the
use of more sophisticated statistical techniques may be able
to determine cause and effect relationships.
Several study limitations need to be acknowledged. The
relatively small sample size and heterogeneous population
limited the use of multivariate methods to predict decre-
ments in HRQOL. Despite these limitations, this study adds
to the growing body of knowledge of the factors that affect
HRQOL. Future research should focus on patients who are
similar with respect to diagnosis and treatment regimen,
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Fig. 1 Patients' scores on the PedsQL™ 3.0 Cancer Module,
completed 1 week after myelosuppressive chemotherapy. All values
are plotted as means ± standard deviations
Table 4 Relationships among PedsQL™ scores and clinical and symptom characteristics
Number of days
hospitalized in
prior week
Number of
relapses
KPS score Number of
symptoms
Mean symptom
severity
Mean symptom
distress
PedsQL™ 4.0 Generic Core Scales
Total score r=−0.15 p=0.27 r=0.13 p=0.32 r=0.63 p<0.001 r=−0.52 p<0.001 r=−0.61 p<0.001 r=−0.64 p<0.001
Physical functioning r=−0.04 p=0.79 r=0.19 p=0.14 r=0.65 p<0.001 r=−0.43 p<0.001 r=−0.53 p<0.001 r=−0.59 p<0.001
Emotional functioning r=0.01 p=0.96 r=0.09 p=0.48 r=0.36 p=0.01 r=−0.47 p<0.001 r=−0.50 p<0.001 r=−0.53 p<0.001
Social functioning r=−0.18 p=0.18 r=−0.03 p=0.80 r=0.56 p<0.001 r=−0.38 p=0.003 r=−0.45 p<0.001 r=−0.47 p<0.001
School functioning r=−0.11 p=0.43 r=0.06 p=0.67 r=0.34 p=0.02 r=−0.31 p=0.02 r=−0.37 p=0.01 r=−0.36 p=0.01
PedsQL™ 3.0 Cancer Module
Total score r=−0.20 p=0.12 r=0.08 p=0.56 r=0.42 p=0.001 r=−0.46 p<0.001 r=−0.48 p<0.001 r=−0.51 p<0.001
Pain and hurt r=0.09 p=0.47 r=0.10 p=0.44 r=0.27 p=0.04 r=−0.26 p=0.04 r=−0.34 p=0.01 r=−0.40 p=0.001
Nausea r=−0.42 p=0.001 r=0.07 p=0.61 r=0.41 p=0.001 r=−0.45 p<0.001 r=−0.52 p<0.001 r=−0.55 p<0.001
Procedural anxiety r=0.16 p=0.22 r=0.14 p=0.28 r=0.11 p=0.39 r=−0.18 p=0.17 r=−0.20 p=0.13 r=−0.22 p=0.09
Treatment anxiety r=0.00 p=1.00 r=−0.03 p=0.85 r=0.29 p=0.03 r=−0.28 p=0.03 r=−0.24 p=0.07 r=−0.29 p=0.02
Worry r=−0.25 p=0.06 r=−0.07 p=0.60 r=0.33 p=0.01 r=−0.33 p=0.01 r=−0.28 p=0.03 p=−0.31 p=0.02
Cognitive Problems r=−0.16 p=0.23 r=0.03 p=0.85 r=0.26 p=0.05 r=−0.26 p=0.04 r=−0.32 p=0.01 r=−0.37 p=0.004
Perceived physical
appearance
r=−0.06 p=0.64 r=0.07 p=0.62 r=0.11 p=0.39 r=−0.19 p=0.14 r=−0.17 p=0.20 r=−0.12 p=0.34
Communication r=−0.20 p=0.13 r=0.08 p=0.54 r=0.35 p=0.01 r=−0.33 p=0.01 r=−0.27 p=0.03 r=−0.25 p=0.06
Support Care Cancer (2011) 19:353–361 359and time since diagnosis in order to eliminate potential
confounding factors. Such a study, with national or
international collaborations, would further delineate the
factors that affect HRQOL in order to identify children who
are at higher risk for decrements in HRQOL and to be
better able to initiate optimal treatment regimens for these
children during cancer CTX.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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